Crinetics Pharmaceuticals Surges After Vertex Agrees to Buy Company for $85 a Share

Web Desk July 6, 2026

0 12 3 minutes read

Crinetics Pharmaceuticals Surges After Vertex Agrees to Buy Company for a Share

Crinetics Pharmaceuticals (CRNX) is up 98.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is Vertex’s agreement to acquire Crinetics in an all-cash deal valued at $85 per share, which immediately reset the stock toward the takeover price. The buyout also highlighted the value of Crinetics’ newly launched acromegaly drug PALSONIFY and late-stage candidate atumelnant, giving investors a clear path to monetization. ([investors.vrtx.com](https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals))

Details:

Vertex and Crinetics announced on July 6, 2026 that they entered a definitive merger agreement under which Vertex will acquire all outstanding CRNX shares for $85.00 in cash, implying about $10.0 billion in equity value. ([investors.vrtx.com](https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals))

Both companies’ boards unanimously approved the transaction, and the deal is expected to close in the third quarter of 2026, subject to regulatory clearance and Crinetics shareholder approval. ([investors.vrtx.com](https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals))

Vertex framed the deal around Crinetics’ commercial and pipeline assets, including PALSONIFY, an oral acromegaly therapy approved in the U.S. in September 2025, and atumelnant, a Phase 3 program for congenital adrenal hyperplasia. ([investors.vrtx.com](https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals))

Vertex said the acquired assets could together exceed $5 billion in peak annual revenue potential, which likely strengthened investor confidence that the offer reflects strategic value rather than a distressed sale. ([investors.vrtx.com](https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals))

Sources:

Vertex Pharmaceuticals, Crinetics Pharmaceuticals, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CRNX Insider Trading Activity

$CRNX insiders have traded $CRNX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $CRNX stock by insiders over the last 6 months:

JEFF E. KNIGHT (Chief Dev. & Operating Officer) has made 0 purchases and 3 sales selling 95,074 shares for an estimated $3,785,447.
RICHARD SCOTT STRUTHERS (President & CEO) has made 0 purchases and 2 sales selling 21,981 shares for an estimated $821,513.
STEPHEN F. BETZ (Chief Scientific Officer) has made 0 purchases and 2 sales selling 10,612 shares for an estimated $396,610.
STEPHANIE OKEY has made 0 purchases and 3 sales selling 9,900 shares for an estimated $365,152.
TOBIN SCHILKE (Chief Financial Officer) sold 6,713 shares for an estimated $266,304
COELHO ROGERIO VIVALDI has made 0 purchases and 2 sales selling 5,000 shares for an estimated $180,760.
ISABEL KALOFONOS (Chief Commercial Officer) sold 2,500 shares for an estimated $137,500

To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$CRNX Hedge Fund Activity

We have seen 141 institutional investors add shares of $CRNX stock to their portfolio, and 87 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BELLEVUE GROUP AG added 3,275,960 shares (+81088.1%) to their portfolio in Q1 2026, for an estimated $118,982,867
POINT72 ASSET MANAGEMENT, L.P. removed 2,337,034 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $84,881,074
PARADIGM BIOCAPITAL ADVISORS LP removed 2,210,774 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $80,295,311
FMR LLC added 1,466,024 shares (+10.3%) to their portfolio in Q1 2026, for an estimated $53,245,991
FARALLON CAPITAL MANAGEMENT LLC added 1,405,000 shares (+20.3%) to their portfolio in Q1 2026, for an estimated $51,029,600
SUVRETTA CAPITAL MANAGEMENT, LLC added 1,043,879 shares (+inf%) to their portfolio in Q1 2026, for an estimated $37,913,685
ADAR1 CAPITAL MANAGEMENT, LLC added 829,963 shares (+268.3%) to their portfolio in Q1 2026, for an estimated $30,144,256

To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CRNX Congressional Stock Trading

Members of Congress have traded $CRNX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CRNX stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative’s congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$CRNX Analyst Ratings

Wall Street analysts have issued reports on $CRNX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citizens issued a “Market Outperform” rating on 01/08/2026

To track analyst ratings and price targets for $CRNX, check out Quiver Quantitative’s $CRNX forecast page.

$CRNX Price Targets

Multiple analysts have issued price targets for $CRNX recently. We have seen 6 analysts offer price targets for $CRNX in the last 6 months, with a median target of $82.5.

Here are some recent targets:

Ashwani Verma from UBS set a target price of $55.0 on 07/02/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $81.0 on 06/15/2026
Jonathan Wolleben from Citizens set a target price of $95.0 on 06/11/2026
Maneka Mirchandaney from Evercore ISI Group set a target price of $88.0 on 05/15/2026
Leland Gershell from Oppenheimer set a target price of $84.0 on 05/11/2026
Richard Law from Goldman Sachs set a target price of $67.0 on 01/12/2026

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.